Court Strikes HRSA 340B Policy Restricting Initial Hospital Drug Purchases Through GPOs

Why It Matters

The ruling restores flexibility for 340B hospitals to leverage GPO pricing, potentially expanding drug‑cost savings and reshaping pharmacy procurement strategies across the safety‑net sector.

Key Takeaways

• Court vacated HRSA’s 2013 GPO prohibition for 340B hospitals
• Ruling deems simultaneous 340B and GPO purchases unlawful restriction
• HRSA must redo rulemaking complying with the Administrative Procedures Act
• Disproportionate share hospitals may resume initial drug purchases via GPOs
• Decision could reshape 340B pricing savings and hospital pharmacy economics

Pulse Analysis

The 340B Drug Pricing Program, administered by HRSA, enables qualifying hospitals to purchase outpatient medicines at steep discounts, offsetting care for underserved populations. In 2013, HRSA added a “GPO prohibition” that prevented these hospitals from simultaneously buying the same drugs through a group purchasing organization, a move intended to prevent duplicate discounts but criticized for limiting hospitals’ negotiating power. Over the past decade, the rule has sparked litigation, with providers arguing that the restriction inflates acquisition costs and hampers access to essential therapies.

The March 31 decision by the District Court for the District of Columbia struck down the GPO prohibition as exceeding HRSA’s statutory authority. The court emphasized that any rule change must adhere to the Administrative Procedures Act, requiring transparent notice‑and‑comment processes. By vacating the provision, the court opened the door for disproportionate‑share hospitals to once again tap GPO contracts for initial drug purchases, potentially unlocking additional savings that were previously foregone under the 2013 policy.

Industry analysts anticipate that the ruling will trigger a wave of procurement restructuring as hospitals reassess their supply‑chain strategies. With the ability to combine 340B discounts and GPO pricing, hospitals could achieve deeper cost reductions, improving margins and freeing resources for patient services. However, HRSA’s forthcoming rulemaking will be closely watched; a revised policy that balances anti‑duplication concerns with market flexibility could set a new benchmark for federal drug‑pricing programs nationwide. Stakeholders should prepare for a period of regulatory uncertainty while positioning for the anticipated savings opportunities.